Search

People with multiple myeloma (MM) often experience disease symptoms and treatment toxicities that can be alleviated through physical activity (PA). However, the majority of people with MM are insufficiently active. This study explored PA among people with MM, including differences by treatment stage, symptoms and demographics, and programming preferences. Overall, 126 people with MM (77% response rate) completed the survey. Pre-diagnosis, 25.4% were sufficiently active, with 12.0% remaining active after treatment. Respondents who were physically active pre-diagnosis were 46.7 times (95% confidence intervals CI: 2.03, 1072.1) more likely to meet PA guidelines following an MM diagnosis compared to people not meeting guidelines pre-diagnosis. Experiencing MM symptoms and receiving PA advice from healthcare professionals were not associated with meeting PA guidelines. People with MM were interested in exercise programs (55%) that are low-cost (77%), offered at flexible times (74%), and at locations close to home (69%), both during active treatment and remission (57%), and supervised by an exercise oncology specialist (48%). People with MM, particularly those insufficiently active prior to diagnosis, should be offered convenient, low-cost exercise programs supervised by an exercise oncology specialist to increase PA participation.

Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment toxicities. Daratumumab is a monoclonal antibody approved for the treatment of MM in the relapsed/refractory setting. Clinical studies found that daratumumab showed good tolerability as a monotherapy and in combination with current standard therapies. However, the administration of daratumumab does require specific management considerations. It is administered as an intravenous infusion and infusion-related reactions (IRRs) may occur. Daratumumab also interferes with routine blood transfusion tests, giving false positives for the indirect antiglobulin test. This article highlights key nursing care considerations and practical management aspects to improve the treatment experience of patients receiving daratumumab infusions. Pretreatment aspects, patient education, pre- and post-medication, daratumumab administration, and the management of IRRs are discussed. An IRR management sheet that could be used by nurses and a patient information sheet are located at the end of this article.

Introduction An increasing number of complex treatment regimens are utilized for the management of multiple myeloma (MM). Treatment schedules include multiple drugs, supportive measures, pathology tests and clinician reviews, however there is no universal scheduling template for Australian use. The Myeloma Specialist Practice Network (M-SPN) of the Haematology Society of Australia and New Zealand (HSANZ) works toward improving quality nursing care and outcomes for individuals with MM. Aim: To develop an online tool for clinicians to create individual MM treatment schedules to be printed and provided to patients to aid understanding, improve adherence and enhance myeloma patient care Method The M-SPN partnered with a health technology platform, myINTERACT to develop and deliver the online tool MyeTxScheduler. A nurse member working group developed content based on Cancer Institute NSW Cancer Treatments Online (eviQ) and real-world clinical experience. Standard MM protocols are included with ability to amend as clinically indicated. Patient identifiers are not included but added after printing. A recent update improved speed, functionality, added new standard protocols and provides links to additional patient information. 3 Haematologists and 2 oncology pharmacists provided content review. Patients provided input on final schedules. Results MyeTxScheduler is distributed through HSANZ membership but available to all clinicians as free download on iOS / Android tablet devices or online populating through the myINTERACT digital platform. 26 standard protocols provide pre-populated MM schedules. Users can amend each item, save, edit and clone schedules. Capacity to add additional drugs and amend notes allows flexibility for real world clinical application. Access MyeTxScheduler at https://rego.interact.technology/myetx/ Conclusion MyeTxScheduler enables clinicians the ability to create individualized treatment schedules to provide to their patients at the point of care, promoting and enhancing quality patient care and nurse understanding of the complex myeloma treatment journey.

Patients with multiple myeloma (MM) often suffer from disease symptoms and treatment toxicities that may be alleviated through physical activity (PA). The attitudes and practices of treating physicians and their patients regarding PA participation for MM patients remains to be elucidated. This study aimed to explore the perspectives of hematologists and patients on PA for patients diagnosed with MM to assist with the development of an individualized, supervised exercise intervention as standard care. Paper-based surveys, with responses rated on a 5-point Likert scale, were distributed to clinical hematologists across Australia, and to patients with MM at public and private clinics. The hematologist survey asked questions regarding the importance of, or agreeance to, the benefits and barriers of PA participation. The patient survey included questions regarding the incidence of disease symptoms and personal perspectives and preferences for the design of an exercise program. Patients with MM (n=119; 79% response rate) and hematologists (n=34; 68% response rate) completed the surveys. The hematologists cumulatively treated approximately 340 patients each week. The patient population was well-represented in the older age groups with 57% aged 65 years or older. Almost all hematologists (97%) agreed that PA was important for patients with MM, with 85% reporting at least occasionally recommending PA to their patients. Exercise recommendations by hematologists diverged for MM patients who were experiencing disease complications; 55% did not recommend exercise when patients had spine fractures or were physically unwell. However 44% never referred patients for supervised PA with accredited exercise physiologists (AEP). An overwhelming majority of patient respondents (84%) experienced at least one symptom to a moderate intensity in the past month. Fatigue was experienced with the highest incidence (55%), with nerve symptoms (46%), back pain (44%) and lethargy (44%) also reported. There was a preference for PA programs during both active treatment and remission (69%) and for them to be guided by an AEP with an interest in cancer (62%). Programs of low-cost (91%), with flexible times (82%) and at locations close to home (77%) were considered important features for participation. Utilizing the information gained from the surveys, an exercise intervention has been developed for patients with MM, with 20 participants currently commenced and recruitment continuing. Hematologists perceive PA as very important for MM patients, however often do not recommend exercise for those experiencing disease complications. Patients are interested in participating in PA with a strong preference for convenient, low-cost programs, supervised by accredited exercise professionals. Availability of dedicated MM programs with clear referral pathways will increase the number of MM patients being referred by their hematologists.

e320 Therefore, this presentation at the International Myeloma Workshop aims to: 1) Evaluate the increasing in the blood pressure in patient that are ongoing a treatment with Carfilzomib 2) Highlight the importance of monitoring blood pressure and provide strategies for nurses to manage hypertension and other adverse events carfilzomib related. 3) Develop a care research in MM to educate patient about selfmanagement of hypertension and modified their life style to reduce cardiovascular risk.